The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer
GATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428318824815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045061438373888 |
|---|---|
| author | Franziska Büscheck Maciej Zub Asmus Heumann Claudia Hube-Magg Ronald Simon Dagmar S Lang Doris Höflmayer Emily Neubauer Frank Jacobsen Andrea Hinsch Andreas M Luebke Maria Christina Tsourlakis Guido Sauter Hartwig Huland Markus Graefen Alexander Haese Hans Heinzer Torsten Schlomm Till S Clauditz Eike Burandt Waldemar Wilczak Stefan Steurer Sarah Minner |
| author_facet | Franziska Büscheck Maciej Zub Asmus Heumann Claudia Hube-Magg Ronald Simon Dagmar S Lang Doris Höflmayer Emily Neubauer Frank Jacobsen Andrea Hinsch Andreas M Luebke Maria Christina Tsourlakis Guido Sauter Hartwig Huland Markus Graefen Alexander Haese Hans Heinzer Torsten Schlomm Till S Clauditz Eike Burandt Waldemar Wilczak Stefan Steurer Sarah Minner |
| author_sort | Franziska Büscheck |
| collection | DOAJ |
| description | GATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples. Normal prostate glands were negative to weakly positive. GATA2 staining was found in almost all prostate cancers (95%). Strong GATA2 staining was linked to advanced tumor stage, high classical and quantitative Gleason grade (p < 0.0001 each), positive nodal stage (p = 0.0116), and early biochemical recurrence (p < 0.0001). GATA2 was linked to ERG -fusion-type cancers, with strong GATA2 staining in 29% of ERG-negative and 53% of ERG-positive cancers (p < 0.0001). Separate calculations in 3854 cancers with and 4768 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. GATA2 expression was further linked to androgen receptor expression: Only 8% of androgen receptor-negative, but 56% of strongly androgen receptor expressing cancers had strong GATA2 expression (p < 0.0001). In conclusion, the results of our study demonstrate that increasing GATA2 levels are linked to prostate cancer progression and aggressiveness. The prognostic value of GATA2 is remarkable in ERG-negative cancers. However, the upregulation of GATA2 in ERG-positive cancers makes it unsuitable as a prognostic marker in this patient subset. |
| format | Article |
| id | doaj-art-cae2903c17d44a8db526b5e01a405e88 |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-cae2903c17d44a8db526b5e01a405e882025-08-20T02:54:47ZengSAGE PublishingTumor Biology1423-03802019-07-014110.1177/1010428318824815The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancerFranziska Büscheck0Maciej Zub1Asmus Heumann2Claudia Hube-Magg3Ronald Simon4Dagmar S Lang5Doris Höflmayer6Emily Neubauer7Frank Jacobsen8Andrea Hinsch9Andreas M Luebke10Maria Christina Tsourlakis11Guido Sauter12Hartwig Huland13Markus Graefen14Alexander Haese15Hans Heinzer16Torsten Schlomm17Till S Clauditz18Eike Burandt19Waldemar Wilczak20Stefan Steurer21Sarah Minner22Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Urology, Charité—Universitätsmedizin Berlin, Berlin, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyGATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples. Normal prostate glands were negative to weakly positive. GATA2 staining was found in almost all prostate cancers (95%). Strong GATA2 staining was linked to advanced tumor stage, high classical and quantitative Gleason grade (p < 0.0001 each), positive nodal stage (p = 0.0116), and early biochemical recurrence (p < 0.0001). GATA2 was linked to ERG -fusion-type cancers, with strong GATA2 staining in 29% of ERG-negative and 53% of ERG-positive cancers (p < 0.0001). Separate calculations in 3854 cancers with and 4768 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. GATA2 expression was further linked to androgen receptor expression: Only 8% of androgen receptor-negative, but 56% of strongly androgen receptor expressing cancers had strong GATA2 expression (p < 0.0001). In conclusion, the results of our study demonstrate that increasing GATA2 levels are linked to prostate cancer progression and aggressiveness. The prognostic value of GATA2 is remarkable in ERG-negative cancers. However, the upregulation of GATA2 in ERG-positive cancers makes it unsuitable as a prognostic marker in this patient subset.https://doi.org/10.1177/1010428318824815 |
| spellingShingle | Franziska Büscheck Maciej Zub Asmus Heumann Claudia Hube-Magg Ronald Simon Dagmar S Lang Doris Höflmayer Emily Neubauer Frank Jacobsen Andrea Hinsch Andreas M Luebke Maria Christina Tsourlakis Guido Sauter Hartwig Huland Markus Graefen Alexander Haese Hans Heinzer Torsten Schlomm Till S Clauditz Eike Burandt Waldemar Wilczak Stefan Steurer Sarah Minner The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer Tumor Biology |
| title | The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer |
| title_full | The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer |
| title_fullStr | The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer |
| title_full_unstemmed | The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer |
| title_short | The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer |
| title_sort | independent prognostic impact of the gata2 pioneering factor is restricted to erg negative prostate cancer |
| url | https://doi.org/10.1177/1010428318824815 |
| work_keys_str_mv | AT franziskabuscheck theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT maciejzub theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT asmusheumann theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT claudiahubemagg theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT ronaldsimon theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT dagmarslang theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT dorishoflmayer theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT emilyneubauer theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT frankjacobsen theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT andreahinsch theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT andreasmluebke theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT mariachristinatsourlakis theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT guidosauter theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT hartwighuland theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT markusgraefen theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT alexanderhaese theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT hansheinzer theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT torstenschlomm theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT tillsclauditz theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT eikeburandt theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT waldemarwilczak theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT stefansteurer theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT sarahminner theindependentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT franziskabuscheck independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT maciejzub independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT asmusheumann independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT claudiahubemagg independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT ronaldsimon independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT dagmarslang independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT dorishoflmayer independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT emilyneubauer independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT frankjacobsen independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT andreahinsch independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT andreasmluebke independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT mariachristinatsourlakis independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT guidosauter independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT hartwighuland independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT markusgraefen independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT alexanderhaese independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT hansheinzer independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT torstenschlomm independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT tillsclauditz independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT eikeburandt independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT waldemarwilczak independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT stefansteurer independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer AT sarahminner independentprognosticimpactofthegata2pioneeringfactorisrestrictedtoergnegativeprostatecancer |